# CalciMedica, Inc. (CALC) — capital_raise/private_placement [announced]
Source: SEC API (secapi.ai) · situation sit_b93a27808f8a7189ceeb · retrieved 2026-08-14T01:25:37.844Z

## Overview
CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases.

CalciMedica, Inc. announced on June 24, 2026, a private placement financing of up to approximately $49 million in gross proceeds, with approximately $15 million in upfront gross proceeds. The proceeds are designated to support the advancement of Auxora and CM5480 as part of the company's pulmonary hypertension strategy, including a planned Phase 1b proof-of-concept trial in pulmonary arterial hypertension and continued development of CM5480 as an oral therapy for chronic use.

## Terms
- Deal value: $49.0M

## Key dates
- Announced 2026-08-11

## Timeline
- 2026-08-11 · 8-K (0001193125-26-343428): 8-K - CalciMedica, Inc. — *CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases.* CalciMedica, Inc. announced on June 24, 2026, a private placement financing of up to approximately $49 million in gross proceeds, with approximately $15 million in upfront gross proceeds. The proceeds are designated to support the advancement of Auxora and CM5480 as part of the company's pulmonary hypertension strategy, including a planned Phase 1b proof-of-concept trial in pulmonary arterial hypertension and continued development of CM5480 as an oral therapy for chronic use.
  https://www.sec.gov/Archives/edgar/data/1534133/0001193125-26-343428.txt

## Citations
- 0001193125-26-343428 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526343428